TABLE 6.
Examined relationship | Group | R Spearman |
p-value |
Se & AGE | BD | −0.32 | 0.039* |
HC | 0.37 | 0.040* | |
Se & DT | BD | −0.50 | < 0.001* |
HC | 0.17 | 0.356 | |
Se & KN | BD | −0.38 | 0.015* |
HC | 0.22 | 0.251 | |
Se & NFK | BD | −0.13 | 0.424 |
HC | 0.38 | 0.038* | |
Se & TAC | BD | −0.33 | 0.031* |
HC | −0.65 | 0.732 | |
Se & TRY | BD | −0.39 | 0.012* |
HC | −0.01 | 0.950 | |
Se & CAT | BD | 0.14 | 0.365 |
HC | 0.38 | 0.040* | |
Zn & 3-NT | BD | 0.27 | 0.079 |
HC | 0.43 | 0.019* | |
Zn & TAC | BD | −0.15 | 0.352 |
HC | −0.43 | 0.017* | |
Zn & CAT | BD | 0.14 | 0.389 |
HC | 0.50 | 0.006* | |
As & NFK | BD | 0.44 | 0.004* |
HC | 0.29 | 0.122 |
BD, bipolar disorder; HC, healthy controls; Se, selenium; Zn, zinc; As, arsenic; AGE, advanced glycation end products; DT, dityrosine; KN, kynurenine; NFK, N-formyl kynurenine; TAC, total antioxidant capacity; TRY, tryptophan; CAT, catalase;
*significant relationship.